Literature DB >> 14755776

Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.

Paul H Hayashi1, James F Trotter, Lisa Forman, Marcelo Kugelmas, Tracy Steinberg, Paul Russ, Michael Wachs, Thomas Bak, Igal Kam, Gregory T Everson.   

Abstract

The allocation system based on the Model for End-stage Liver Disease (MELD) has led to more patients diagnosed with hepatocellular carcinoma (HCC) being transplanted. We hypothesized that more patients misdiagnosed with HCC are also being transplanted, leading to inappropriate organ allocation. Therefore, we retrospectively analyzed all liver transplants at our center from July 14, 2000, to October 22, 2002 (N = 172; 129 pre-MELD, 43 post-MELD), comparing pretransplant HCC diagnosis to explant histology. Thirty patients met the United Network for Organ Sharing (UNOS) diagnostic criteria for pretransplant HCC diagnosis. There were 25 men (median age, 52.5 yr), and 80% had hepatitis C. The proportion of patients transplanted who had an HCC diagnosis increased from 12% (15/129) pre-MELD to 35% (15/43) post-MELD implementation (P < 0.01). Three of 15 (20%) transplanted pre-MELD and 5 of 15 (33%) transplanted post-MELD lacked HCC in the explant (P = 0.10). Of the three false-positives pre-MELD, one was Status 2B already, and two received living-donor livers. Of the 5 false-positives post-MELD, three had score upgrades that led to early transplantation (13 to 29, 20 to 29, and 9 to 24) while two had MELD scores of 35 and 36 already. The percentage of organs that could have gone to patients with more advanced liver disease without HCC increased from 0% (0/129) pre-MELD to 7% (3/43) post-MELD (P < 0.01). Since the implementation of MELD, the proportion of patients transplanted who had an HCC diagnosis nearly tripled, and a small but significant proportion of organs are now going to patients misdiagnosed with HCC. More stringent HCC diagnostic criteria will be required to decrease the effect that misdiagnosis has on organ allocation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755776     DOI: 10.1002/lt.20020

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  20 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma.

Authors:  Nader N Massarweh; James O Park; Jordi Bruix; Raymond S W Yeung; Ruth B Etzioni; Rebecca Gaston Symons; Laura-Mae Baldwin; David R Flum
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

Review 3.  Emerging Role of the Pathologist in Precision Medicine for HCC.

Authors:  Thomas Longerich; Peter Schirmacher
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

4.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 5.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Contrast-enhanced 3D ultrasonography in minute hepatocellular carcinoma.

Authors:  Masao Ohto; Ryu Ito; Nei Soma; Hiroyuki Fukuda; Yasushi Shinohara; Akio Sakamoto; Fukuo Kondo
Journal:  J Med Ultrason (2001)       Date:  2010-09-16       Impact factor: 1.314

7.  Clinical impact of an adaptive statistical iterative reconstruction algorithm for detection of hypervascular liver tumours using a low tube voltage, high tube current MDCT technique.

Authors:  Daniele Marin; Kingshuk Roy Choudhury; Rajan T Gupta; Lisa M Ho; Brian C Allen; Sebastian T Schindera; James G Colsher; Ehsan Samei; Rendon C Nelson
Journal:  Eur Radiol       Date:  2013-07-06       Impact factor: 5.315

Review 8.  Liver transplantation as a management of hepatocellular carcinoma.

Authors:  Ayman Zaki Azzam
Journal:  World J Hepatol       Date:  2015-06-08

9.  Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.

Authors:  Satoru Todo; Hiroyuki Furukawa
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

10.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.